GLP-1 medications and hair shedding

Short answer: more hair comes out than usual for some people on a GLP-1 medication such as Ozempic, Wegovy, Mounjaro or Zepbound, and the pattern reported almost every time is telogen effluvium — a temporary shedding phase, not balding. The best current explanation is the speed at which body weight comes down, not the drug acting on the follicle. It typically starts two to four months after the change and settles within six to nine months.

Hair is made of protein, and it is built from the same intake as everything else, which is why this topic sits inside our guide to what to eat when you're eating less. If your appetite has fallen off a cliff, the shedding and the half-empty plate are probably the same story.

Shedding and balding are not the same thing

Everyone loses hair every day. The American Academy of Dermatology puts normal shedding at 50 to 100 hairs a day.¹ Telogen effluvium is what happens when a much larger share of your follicles switch out of their growing phase at the same time, because of something that happened to the whole body. Three or so months later, all of those hairs let go together, and you find them in the shower drain in handfuls.

Two features make it recognisable, and they are both reassuring:

• It is diffuse. The whole scalp thins a little. You are not developing a bald patch or a receding front — those are different conditions with different causes.
• The follicle is intact. The hair has been pushed out, not killed off. When the trigger passes, the follicles go back to growing.

The AAD's own list of triggers includes giving birth, high fever, surgery, recovering from an illness, severe stress — and dropping 20 lb or more.¹ Shedding tends to begin a few months after the event, peaks around four months, and hair "tends to regain its normal fullness" within six to nine months.¹ That delay is the cruel part: by the time you notice, the thing that caused it was a season ago.

What the research on GLP-1 medications actually found

Three pieces of work from 2025 and 2026 are worth knowing about, and none of them is a randomised trial.

A retrospective cohort study using the TriNetX records network matched adults taking semaglutide or tirzepatide against comparable adults who were not, and looked for new diagnoses of hair loss. Both drugs were associated with higher odds of non-scarring hair loss, and of telogen effluvium specifically. Two details in that paper matter more than the headline. Alopecia areata — an autoimmune condition with no plausible link to eating less — was included as a negative control and showed no association, which argues against the whole finding being an artefact. And among the people taking these medications, those who developed hair loss had a lower follow-up BMI than those who did not.²

The people who shed were the people whose weight came down fastest. That points at the pace of change, not at the prescription.

A systematic review published in 2026 screened 133 studies and included 24. Semaglutide and tirzepatide showed the highest reported rates and the strongest signals in pharmacovigilance databases. Androgenetic alopecia and telogen effluvium were the subtypes identified where anyone bothered to classify them. Tirzepatide — the agent that produces the largest reduction in body weight — was the one most often linked to telogen effluvium. The semaglutide reports looked dose-dependent: doses under 2 mg weekly were rarely implicated, while the higher doses used for obesity were. Women appeared to be affected disproportionately.³

A scoping review the same year was blunter about the state of the evidence, calling it conflicting, and noted that risk appeared to rise with longer use, greater reduction in body weight and higher doses. Its proposed mechanisms go beyond nutrition — changes in the fat layer within the skin itself, and hormonal shifts — and it points out that a smaller body of work reports improvement in inflammatory scalp conditions on these drugs.⁴

Honest summary: the association is real enough to counsel people about, the subtype is usually the temporary one, and causation is unproven. These are claims-code studies and adverse-event reports, not dermatologists examining scalps.

The clue is the pace, not the prescription

If this were the medication poisoning follicles, it would be new. It is not new. A meta-analysis of 18 studies covering 2,538 people after metabolic and bariatric surgery found a pooled hair-loss rate of 57% (95% CI 42–71%), falling as follow-up got longer. It was more common in younger women, and it tracked with low blood levels of zinc, folate and ferritin.⁵

No drug involved. Same shedding, at a higher rate than anything reported for GLP-1 medications, in people whose intake dropped suddenly and whose body weight fell fast. That is the context the headlines leave out, and it is also the hopeful part — the surgical literature shows the rate going down over time, because the follicles were never the problem.

The nutrition side, which is the part you can change

You cannot change how quickly your body responds to the medication, and you should not try to slow it down on your own. What you can change is whether the raw materials are arriving. A 2025 joint advisory from four medical societies reports energy intake falling by 16% to 39% on GLP-1 therapy.⁶ A third less food is a third less of everything in it.

Protein first

Hair is keratin, a structural protein, and the body treats hair as optional when protein is short. The adult RDA is 0.8 g per kg of body weight a day, and 1.2 to 1.6 g/kg has been proposed while body weight is coming down.⁶ Hitting that on a small appetite takes planning rather than willpower: tables by body weight and a worked day are in how much protein to eat on a GLP-1. If you are also losing strength, read keeping muscle on a GLP-1 — the two shortfalls have the same cause.

Iron, zinc and folate

These are the three that keep coming up in the shedding literature, and all three are the ones the surgical meta-analysis found low.⁵ Zinc deficiency has hair loss among its recognised signs,⁹ and zinc is one of the minerals on our ingredients page. Folate comes from leafy greens, beans and fortified grain; iron from meat, fish, beans and fortified cereal, better absorbed alongside vitamin C. Which vitamins are most likely to fall short when you eat less, and where to get them from food, is covered in which vitamins matter on a GLP-1.

Test before you supplement

This is the part most hair content skips, because it does not sell anything. A review of diet and hair loss is explicit: screen by history and physical examination, correct deficiencies that are actually documented, and understand that whether supplementing helps in the absence of a deficiency is unproven. It goes further — some supplements carry a risk of making shedding worse, or of toxicity.⁷ Vitamin A and selenium are the usual culprits, and both are easy to overshoot with a stack of products.

A ferritin level, a CBC and a thyroid panel are ordinary, inexpensive tests. Zinc can be added. Guessing in this category is unusually unrewarding, and a blood test is the only thing that turns "maybe I'm low" into a reason to take something. The wider question of what is worth taking at all is in what supplements to take with a GLP-1.

Biotin, and why it is on every shelf

Biotin is in every hair, skin and nails product on the market, and the evidence for it in people who are not deficient is thin. A review of the literature found biotin's efficacy for hair "largely unsubstantiated", while documenting how heavily it is marketed.⁸ True biotin deficiency is rare in people eating an ordinary mixed diet. One practical warning: biotin at supplement doses interferes with some laboratory immunoassays, including thyroid and cardiac tests, so tell whoever is drawing your blood that you are taking it.¹⁰

What a dermatologist will do

• History. When the shedding started, what happened three to four months before that, what you are eating now.
• Examination. Whether the thinning is diffuse or patterned, and a gentle pull test to see how many hairs release.
• Blood work. Ferritin, CBC, thyroid function, sometimes zinc. Not a long panel on a hunch.
• A diagnosis. Telogen effluvium is managed by removing the trigger and waiting. Androgenetic alopecia, which these studies also flagged, is a different condition with actual treatments. Those are opposite answers to the same symptom, which is why guessing is a poor plan.

When to call your prescriber

• Shedding that has not settled nine months after it began.
• Patches, a receding hairline or a widening part — that pattern is not telogen effluvium.
• A sore, burning or itching scalp.
• Other signs that intake is too low: brittle nails, bruising easily, feeling cold, or strength falling away.
• Anything that makes you want to stop the medication. That is a conversation, not a decision to make alone.

A product we are working on

Roots, our planned hair, skin and nails product, is in development and has a waitlist. It is not available yet. It is also not a treatment for shedding, and no supplement is: if the cause is the pace of change, the answer is time, protein and whatever a blood test actually turns up. Replenish, the product we sell today, is a daily hydration and nutrient powder — it is not a hair product.